Pink (100) 
|
SPI1
|
0.83
|
GO:0006952 defense response (P
adj = 6.17e-07)
|
Neutrophils (P = 7.46e-11)
|
|
PLEK
|
GO:0006955 immune response (P
adj = 2.25e-06)
|
Act. neutrophils (P = 4.44e-09)
|
|
HCK
|
IPA path: Fcγ receptor-mediated phagocytosis in macrophages and monocytes (P = 4.97e-10)
|
Eosinophils (P = 3.74e-04)
|
|
FGR
|
IPA upstream regulator: IFNG (P = 4.77e-16)
|
Act. macrophages (P = 9.78e-03)
|
|
TLR4
|
IPA function: leukocyte migration (increased) (P = 3.82e-22)
|
Act. eosinophils (P = 2.67e-02)
|
Blue (726) 
|
SLAMF7
|
0.75
|
GO:0006955 immune response (P
adj = 5.31e-76)
|
Act. macrophages (P = 2.49e-16)
|
|
SP100
|
GO:0006952 defense response (P
adj = 2.15e-29)
|
Dendritic cells (P = 3.01e-11)
|
|
DTX3L
|
GO:0045321 leukocyte activation (P
adj = 3.79e-26)
|
Act. neutrophils (P = 3.78e-05)
|
|
GIMAP4
|
IPA upstream regulator: IFNG (P = 1.66e-100)
|
Neutrophils (P = 1.99e-04)
|
|
OAS3
|
IPA path: interferon signaling (P = 3.35e-22)
|
NK cells (P = 2.64e-02)
|
Black (117) 
|
DCAKD
|
0.28
|
GO:0031982 ~ vesicle (P
adj = 1.38e-02)
|
Act. macrophages (P = 4.06e-03)
|
|
GNA13
|
GO:0012505 endomembrane system (P
adj = 2.10e-02)
|
|
PICALM
|
IPA upstream regulator: CHEK2 (P = 6.49e-05)
|
|
CREB1
|
IPA path: ephrin receptor signaling (P = 3.26e-04)
|
|
LARP4
|
IPA function: viral infection (increased) (P = 1.02e-04)
|
Magenta (85) 
|
TNKS2
|
0.32
|
No significant DAVID enrichments
|
Act. macrophages (P = 4.57e-02)
|
|
VCPIP1
|
IPA path: oxidative phosphorylation (P = 8.05e-05)
|
|
MIER1
|
IPA path: mitochondrial dysfunction (P = 6.51e-04)
|
|
CD2AP
|
IPA path: NF-κB signaling (P = 6.14e-03)
|
|
ARAP2
| |
Yellow (189) 
|
CHST9
|
0.70
|
No significant DAVID enrichments
|
Act. neutrophils (P = 4.00e-04)
|
|
ITGA5
|
IPA function: inflammatory response (P = 2.09e-11)
|
Act. macrophages (P = 9.78e-03)
|
|
C8orf47
|
IPA function: quantity of leukocytes (P = 1.67e-10)
|
Neutrophils (P = 1.56e-02)
|
|
OXSR1
|
IPA function: differentiation of cells (P = 1.74e-10)
|
Act. eosinophils (P = 1.83e-02)
|
|
ITPRIPL2
| | |
Green (179) 
|
RPL10A
|
−0.46
|
GO:0006414 translational elongation (P
adj = 3.65e-44)
|
B cells (P
adj = 1.07e-07)
|
|
RPL3
|
KEGG: hsa03010 ribosome (P
adj = 3.34e-37)
|
Th2 cells (P
adj = 8.30e-05)
|
|
EEF2
|
GO:0006412 translation (P
adj = 7.72e-36)
|
T cells (P
adj = 2.33e-04)
|
|
RPS14
|
IPA path: eIF2 signaling (P = 4.07e-47)
|
Mast cells (P
adj = 1.33e-03)
|
|
RPL4
| |
Th1 cells (P
adj = 2.42e-02)
|
Brown (203) 
|
ELOVL5
|
−0.74
|
Type 2 inflammation (P = 3.30e-04)
|
No significant immune cell enrichments
|
|
CDH26
|
No significant DAVID enrichments
|
|
ALOX15
|
IPA upstream regulator: IL13 (P = 2.77e-05)
|
|
FETUB
| |
|
VWF
| |
Red (164) 
|
CFL1
|
0.50
|
GO:0015629 actin cytoskeleton (P
adj = 2.41e-06)
|
Act. neutrophils (P
adj = 2.35e-02)
|
|
CAP1
|
GO:0031252 cell leading edge (P
adj = 6.68e-05)
|
Act. macrophages (P
adj = 3.04e-02)
|
|
VASP
|
IPA path: remodeling of epithelial adherens junctions (P = 2.42e-09)
| |
|
DIAPH1
|
IPA upstream predictor: TGFB1 (P = 6.88e-09)
| |
|
TMBIM1
|
IPA function: organization of cytoskeleton (increased) (P = 3.65e-15)
| |
Turquoise (1,615) 
|
C6orf165
|
−0.43
|
GO:0005929 cilium (P
adj = 2.78e-30)
|
No significant immune cell enrichments
|
|
ARMC2
|
GO:0015630 microtubule cytoskeleton (P
adj = 1.02e-23)
|
|
CAPSL
|
GO:0005930 axoneme (P = 3.01e-21)
|
|
EFCAB6
|
IPA upstream regulator: RFX3 (P = 1.74e-05)
|
|
ANKRD66
|
IPA function: formation of cilia (decreased) (P = 1.47e-43)
|
